Systemic Inflammatory Response Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Cardiovascular Follow-up of Patients Treated for MIS-C.
The role of macrophages polarization in sepsis-induced acute lung injury.
The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
Multisystem Inflammatory Syndrome in Children in New York State.
Cytokines in Inflammatory Disease.
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2025-12-31Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)Primary completion
- 2025-11-01Effect of a Perioperative Opioid Free Anaesthesia-Analgesia (OFA-A) Strategy on Surgical Stress Response and Immunomodulation in Elective VATS Lobectomy for NSCLC Lung Cancer: A Prospective Randomized StudyPrimary completion
- 2026-06-10ClinicalDouble-blind, Randomized, Placebo-controlled, Pilot Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Two Doses of a Conditioned Medium From a Co-culture of M2-macrophages and Fat-derived Mesenchymal Cells (PRS CK STORM) in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)Results expected Q4 2026
- 2025-12-31ClinicalProtective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)Primary completion
- 2025-11-01ClinicalEffect of a Perioperative Opioid Free Anaesthesia-Analgesia (OFA-A) Strategy on Surgical Stress Response and Immunomodulation in Elective VATS Lobectomy for NSCLC Lung Cancer: A Prospective Randomized StudyPrimary completion
- 2025-10-16ClinicalA Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of Auxora in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response SyndromeResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Periodic fever syndromes Ilaris is indicated for the treatment of the following autoinfla… (2009)
Approval — Rheumatoid Arthritis (RA) Kineret is indicated in adults for the treatment of the signs a… (2002)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Systemic Inflammatory Response Syndrome2
- Acute Lung Injury1
- Coronary Aneurysm1
- COVID-191
- Heart1
- Mucocutaneous Lymph Node Syndrome1
- Nervous System Diseases1
- Organ Dysfunction Scores1
Leading journals6
- Arthritis & rheumatology (Hoboken, N.J.)3
- JAMA2
- Blood1
- BMJ (Clinical research ed.)1
- Cell1
- European journal of pediatrics1
Leading researchers8
- Friedman KG4
- Henderson LA3
- Bassiri H2
- Behrens EM2
- Canna SW2
- Dionne A2
- Ferris A2
- Gorelik M2
Affiliations (unnormalised)6
- University of Pittsburgh School of Medicine3
- American College of Rheumatology2
- Boston Children's Hospital2
- Boston Children's Hospital and Harvard Medical School2
- Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine.2
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Systemic inflammatory response syndrome is a systemic inflammatory response to a range of clinical insults. It is characterized by at least two findings such as fever or hypothermia, tachycardia, tachypnea, and leukocytosis. It is often associated with infection, but it can also occur with noninfectious insults such as trauma, burns, or pancreatitis.
The grounding supports a broad etiologic category rather than a single cause. SIRS can be triggered by infection, and it can also follow noninfectious clinical insults including trauma, burns, and pancreatitis. The literature also links systemic inflammatory states to cytokine-mediated inflammatory disease and critical illness.
The condition reflects a systemic inflammatory state with involvement of inflammatory cytokines. The supplied reviews describe cytokines such as IL-6, IL-1, IL-33, TNF-α, IL-10, and IL-8 as mediators implicated in inflammatory disease, shock, trauma, immune dysregulation, and critical illness. In this context, SIRS is associated with cytokine-driven inflammation and, when severe, can be accompanied by widespread organ dysfunction.
The grounding supports exposure to clinical insults that can precipitate SIRS, including infection, trauma, burns, and pancreatitis. It also supports severe inflammatory states and critical illness as associated contexts. No additional patient-level risk factors are supported by the supplied material.
The supplied material supports supportive management and treatment directed at the underlying trigger, but it does not provide a detailed standard regimen for SIRS itself. In related inflammatory syndromes, management may include immunomodulatory therapy and supportive care, and cytokines are discussed as potential biomarkers and therapeutic parameters. No specific drug class is established in the grounding as standard therapy for SIRS.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever >38 degrees C or HYPOTHERMIA <36 degrees C; (2) TACHYCARDIA >90 beat/minute; (3) tachypnea >24 breaths/minute; (4) LEUKOCYTOSIS >12,000 cells/cubic mm or 10% immature forms. While usually related to infection, SIRS can also be associated with noninfectious insults such as TRAUMA; BURNS; or PANCREATITIS. If infection is involved, a patient with SIRS is said to have SEPSIS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.